AMD prediction a step closer using nature or nuture variables

Article

Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables.

Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables, according to research published in Investigative Ophthalmology & Visual Science.

1446 individuals were evaluated, of which 279 went on to develop advanced AMD over a 6.3 year period. The researchers took into account factors such as smoking, age, sex, education and body mass index to compile their predictive model.

As reported in Science Daily, lead author Johanna Seddon MD, ScM, Professor of Ophthalmology at Tufts University School of Medicine said: "The determinants of the model can be assessed by completing a questionnaire and taking a blood test, and it is a tool which could be used to help guide prevention and treatments. Our algorithm could help with the selection of study participants for treatment trials and could one day enable doctors to choose the most efficacious treatment for individual patients. It also gives any older person concerned about AMD, or any patient with early stages or a family history of AMD, even more incentive to avoid risk factors such as smoking and excessive weight."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.